Phreesia Investors Face July 13 Deadline in Securities Class Action

The legal action, spearheaded by Faruqi & Faruqi, LLP, alleges that Phreesia executives provided overly optimistic outlooks regarding its Network Solutions segment and the AccessOne acquisition. While the company touted expansion, the complaint suggests they simultaneously concealed slowing demand and weakened pharmaceutical marketing commitments. This alleged lack of transparency culminated on March 30, 2026, when the firm issued a downward revision of its fiscal year 2027 revenue guidance.

Following the announcement, Phreesia shares dropped from $11.41 to $8.38—a 27% decline in market value. Investors who suffered losses during the specified class period are encouraged to contact partner Josh Wilson at 877-247-4292 or 212-983-9330 to discuss their options. While the court will appoint a lead plaintiff to oversee the case, shareholders are not required to take individual legal action to remain part of the class or potentially share in a future recovery.